D
David J. Mauro
Researcher at Merck & Co.
Publications - 51
Citations - 4427
David J. Mauro is an academic researcher from Merck & Co.. The author has contributed to research in topics: Cetuximab & Cancer. The author has an hindex of 21, co-authored 48 publications receiving 4164 citations. Previous affiliations of David J. Mauro include United States Military Academy & Bristol-Myers Squibb.
Papers
More filters
Journal ArticleDOI
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
Christine H. Chung,Beloo Mirakhur,Emily Chan,Quynh-Thu Le,Jordan Berlin,Michael A. Morse,Barbara A. Murphy,S.M. Satinover,Jacob D. Hosen,David J. Mauro,Robbert J.C. Slebos,Qinwei Zhou,Diane R. Gold,Tina Hatley,Daniel J. Hicklin,Thomas A.E. Platts-Mills +15 more
TL;DR: In most subjects who had a hypersensitivity reaction to cetuximab, IgE antibodies against cetUXimab were present in serum before therapy, and the antibodies were specific for galactose-alpha-1,3-galactose.
Journal ArticleDOI
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.
Shirin Khambata-Ford,Christopher R. Garrett,Neal J. Meropol,Mark Basik,Christopher T. Harbison,Shujian Wu,Tai W. Wong,Xin Huang,Chris H. Takimoto,Andrew K. Godwin,Benjamin R. Tan,Smitha S. Krishnamurthi,Howard A. Burris,Elizabeth Poplin,Manuel Hidalgo,José Baselga,Edwin A. Clark,David J. Mauro +17 more
TL;DR: Gene expression profiles showed that patients with tumors that express high levels of the EGFR ligands epiregulin and amphireGulin and patients with wild-type K-ras are more likely to have disease control on cetuximab treatment.
Journal ArticleDOI
Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines
Heinz-Josef Lenz,Eric Van Cutsem,Shirin Khambata-Ford,Robert J. Mayer,Philip J. Gold,Philip Stella,B. Mirtsching,Allen Lee Cohn,Andrew William Pippas,Nozar Azarnia,Zenta Tsuchihashi,David J. Mauro,Eric K. Rowinsky +12 more
TL;DR: Cetuximab is active and well tolerated in metastatic CRC refractory to irinotecan, oxaliplatin, and fluoropyrimidines and neither EGFR kinase domain mutations nor EGFR gene amplification appear to be essential for response to cetUXimab in this setting.
Journal ArticleDOI
Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results.
Susan L. Boone,Alfred Rademaker,Dachao Liu,Carmen Pfeiffer,David J. Mauro,Mario E. Lacouture +5 more
TL;DR: The survey results support that attentive cutaneous care is important in patients treated with EGFR inhibitors, and that proactive/combined interventions may enhance quality of life and optimize consistent drug administration.
Journal ArticleDOI
A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: Pharmacokinetic and pharmacodynamic rationale for dosing
Paula M. Fracasso,Howard A. Burris,Matthew A. Arquette,Ramaswamy Govindan,Feng Gao,Lisa P. Wright,Sherry A. Goodner,F. Anthony Greco,Suzanne F. Jones,Noel Willcut,Catherine Chodkiewicz,Amit P Pathak,Gregory M. Springett,George R. Simon,Daniel M. Sullivan,Raphael Marcelpoil,Shelley Mayfield,David J. Mauro,Christopher R. Garrett +18 more
TL;DR: In this paper, a phase 1 study evaluated the pharmacokinetic and pharmacodynamic effects of cetuximab on patients with epithelial malignancies following a skin and tumor biopsy.